Physician profile
Jonathan Y Chen
NPI 1518995984
$5,115.84
in general payments reported to CMS, 2019-2025
34 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $416 · 2021: $145 · 2022: $989 · 2023: $879 · 2024: $825 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,575.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,371.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.71 | 2019-2025 | Ofev, Jascayd, Combivent Respimat |
| Genzyme Corporation | $599.10 | 2019-2025 | |
| Grifols USA, LLC | $595.80 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Astrazeneca Pharmaceuticals LP | $465.08 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $188.82 | 2020-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $162.92 | 2019-2022 | |
| Mylan Specialty L.P. | $155.28 | 2019-2024 | Yupelri |
| Sun Pharmaceutical Industries INC. | $104.26 | 2022 | |
| Mallinckrodt Enterprises LLC | $87.69 | 2019 | |
| Insmed, INC. | $70.80 | 2019-2023 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $65.01 | 2022-2024 | Glassia |
| Baxter Healthcare | $51.71 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $49.97 | 2023-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $42.64 | 2023-2024 | Purified Cortrophin Gel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $40.54 | 2020 | |
| Boston Scientific Corporation | $35.76 | 2023 | Ekosonic |
| Circassia INC. | $32.50 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.87 | 2021 | |
| Alcon Vision LLC | $27.58 | 2025 | Precision7 |
| La Jolla Pharmaceutical Company | $26.55 | 2019-2023 | Giapreza |
| Genentech USA, INC. | $25.24 | 2019-2022 | |
| Vapotherm INC | $25.11 | 2022 | |
| Inari Medical, INC. | $23.88 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Covis Pharma Gmbh | $23.39 | 2022 | |
| United Therapeutics Corporation | $23.24 | 2022 | |
| Merck Sharp & Dohme LLC | $22.74 | 2023 | |
| Sunovion Pharmaceuticals INC. | $19.92 | 2019 | |
| Pulmonx Corporation | $19.63 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Shire North American Group INC | $17.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.13 | 2019 | |
| Seagen INC. | $15.68 | 2019 | |
| Viatris Specialty LLC | $14.07 | 2025 | Yupelri |
| Nabriva Therapeutics, Plc | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.